陈文;周洲;
CHEN Wen;ZHOU Zhou;Center of Laboratory Medicine, State Key Laboratory of Cardiovascular Diseases, Beijing Key Laboratory for Molecular Diagnostics of Cardiovascular Diseases, Fuwai Hospital, Chinese Academy of Medical Sciences &Peking Union Medical College, National Center for Cardiovascular Diseases;

• 1:国家心血管病中心中国医学科学院阜外医院实验诊断中心心血管疾病国家重点实验室心血管疾病分子诊断北京市重点实验室

摘要(Abstract)：

精准医疗是在诊疗过程中充分考虑患者个体在基因、环境、生活方式等方面差异的医学手段,基因检测是实现精准医疗的重要方式。自人类基因组数据成功解析以来,人们对遗传因素在心血管疾病发生、发展和转归中的作用有了更深刻的认识。迅速崛起的精准医疗围绕心血管疾病的预防和治疗,将基础医学、临床医学和转化医学有机结合,不仅推动了心血管疾病遗传学研究的快速进展,且为制定个体化疾病诊疗方案奠定了基础。遗传变异和基因多态性是冠心病的重要发病因素,基因检测不仅可识别冠心病高危人群,且能够针对不同分子病理途径制定最佳预防和治疗策略,进而促进精准医学的应用。本文将着重介绍基因检测在冠心病及其相关危险因素预防、诊断和治疗中的作用。
Precision medicine is a medical method that fully considers the differences of individual patients in gene, environment, life style, and so on in the process of diagnosis and treatment. Gene testing is an important way to realize precision medicine. Since the human genome data was analyzed, people have a deeper understanding of the role of genetic factors in the occurrence, development and prognosis of cardiovascular diseases. The emerging precision medicine improves the prevention and treatment of diseases through big data, promotes the progress of genetic research on cardiovascular diseases, and sets the foundation of individualized medicine, which organically combines clinical medicine, basic medicine, and transformational medicine. Genetic variation and gene polymorphism are important factors leading to coronary heart disease. We can not only identify people at high risk of coronary heart disease, but also formulate the best prevention and treatment strategies according to different molecular pathological pathways by genetic detection. All of these approaches promote the application of precision medicine. This review focused on the application of genetic testing in the prevention, diagnosis, and treatment of coronary heart disease and its related diseases.

关键词(KeyWords)： 基因检测;冠心病;精准医疗;风险预测;心血管药物基因组
genetic testing;coronary heart disease;precision medicine;risk prediction;cardiovascular pharmacogenomics

Abstract:

Keywords:

基金项目(Foundation): 国家自然科学基金(82070326);; 中国医学科学院医学与健康科技创新工程(2016-I2M-1-016)~~

作者(Authors): 陈文;周洲;
CHEN Wen;ZHOU Zhou;Center of Laboratory Medicine, State Key Laboratory of Cardiovascular Diseases, Beijing Key Laboratory for Molecular Diagnostics of Cardiovascular Diseases, Fuwai Hospital, Chinese Academy of Medical Sciences &Peking Union Medical College, National Center for Cardiovascular Diseases;

参考文献(References)：

• [1] 中国心血管健康与疾病报告编写组.中国心血管健康与疾病报告2019概要[J].中国循环杂志，2020,35:833- 852.The Writing Committee of the Report on Cardiovascular Health Diseases in China.Summary of China Cardiovascular Health and Disease Report 2019[J].Zhongguo Xunhuan Zazhi,2020,35:833- 852.
• [2] Truett J,Cornfield J,Kannel W.A multivariate analysis of the risk of coronary heart disease in Framingham[J].J Chronic Dis,1967,20:511- 524.
• [3] Andersson C,Johnson AD,Benjamin EJ,et al.70-year legacy of the Framingham Heart Study[J].Nat Rev Cardiol,2019,16:687- 698.
• [4] Chambless LE,Folsom AR,Sharrett AR,et al.Coronary heart disease risk prediction in the Atherosclerosis Risk in Communities (ARIC) study[J].J Clin Epidemiol,2003,56:880- 890.
• [5] Scheltens T,Verschuren WM,Boshuizen HC,et al.Estimation of cardiovascular risk:a comparison between the Framingham and the SCORE model in people under 60 years of age[J].Eur J Cardiovasc Prev Rehabil,2008,15:562- 566.
• [6] 中国心血管病风险评估和管理指南编写联合委员会.中国心血管病风险评估和管理指南[J].中华预防医学杂志，2019,34:4- 28.Chinese Joint Committee on the Preparation of Guidelines for Risk Assessment and Management of Cardiovascular Disea-ses.The Joint Task Force for Guideline on the Assessment and Management of Cardiovascular Risk in China[J].Zhonghua Yufang Yixue Zazhi,2019,34:4- 28.
• [7] 刘晓聪，冯颖青，陈纪言.心血管疾病风险评估模型研究进展[J].中国实用内科杂志，2021,41:428- 433.Liu XC,Feng YQ,Chen JY.Advances in cardiovascular disease risk assessment models[J].Zhongguo Shiyong Neike Zazhi,2021,41:428- 433.
• [8] Nomura A,Sato T,Tada H,et al.Polygenic risk scores for low-density lipoprotein cholesterol and familial hypercholesterolemia[J].J Human Genetics,2021.doi:10.1038/s10038- 021- 00929- 7.[Epub ahead of print].
• [9] Elliott J,Bodinier B,Bond TA,et al.Predictive Accuracy of a Polygenic Risk Score-Enhanced Prediction Model vs a Clinical Risk Score for Coronary Artery Disease[J].JAMA,2020,323:636- 645.
• [10] Teslovich TM,Musunuru K,Smith AV,et al.Biological,clinical and population relevance of 95 loci for blood lipids[J].Nature,2010,466:707- 713.
• [11] Willer CJ,Schmidt EM,Sengupta S,et al.Discovery and refinement of loci associated with lipid levels[J].Nat Genet,2013,45:1274- 1283.
• [12] Sun D,Zhou T,Heianza Y,et al.Type 2 Diabetes and Hypertension[J].Circ Res,2019,124:930- 937.
• [13] Saleheen D,Zhao W,Young R,et al.Loss of Cardioprotective Effects at the ADAMTS7 Locus as a Result of Gene-Smoking Interactions[J].Circulation,2017,135:2336- 2353.
• [14] Roberts R,Chang CC,Hadley T.Genetic Risk Stratification:A Paradigm Shift in Prevention of Coronary Artery Disease[J].JACC Basic Transl Sci,2021,6:287- 304.
• [15] Koyama S,Ito K,Terao C,et al.Population-specific and trans-ancestry genome-wide analyses identify distinct and shared genetic risk loci for coronary artery disease[J].Nat Genet,2020,52:1169- 1177.
• [16] Mega JL,Stitziel NO,Smith JG,et al.Genetic risk,coronary heart disease events,and the clinical benefit of statin therapy:an analysis of primary and secondary prevention trials[J].Lancet,2015,385:2264- 2271.
• [17] Khera AV,Emdin CA,Drake I,et al.Genetic Risk,Adherence to a Healthy Lifestyle,and Coronary Disease[J].N Engl J Med,2016,375:2349- 2358.
• [18] Mega JL,Stitziel NO,Smith JG,et al.Genetic risk,coronary heart disease events,and the clinical benefit of statin therapy:an analysis of primary and secondary prevention trials[J].Lancet,2015,385:2264- 2271.
• [19] Nelson CP,Goel A,Butterworth AS,et al.Association analyses based on false discovery rate implicate new loci for coronary artery disease[J].Nat Genet,2017,49:1385- 1391.
• [20] Abraham G,Havulinna AS,Bhalala OG,et al.Genomic prediction of coronary heart disease[J].Eur Heart J,2016,37:3267- 3278.
• [21] Wang J,Dron JS,Ban MR,et al.Polygenic Versus Monogenic Causes of Hypercholesterolemia Ascertained Clinically[J].Arterioscler Thromb Vasc Biol,2016,36:2439- 2445.
• [22] Berberich AJ,Hegele RA.The complex molecular genetics of familial hypercholesterolaemia[J].Nat Rev Cardiol,2019,16:9- 20.
• [23] Hu P,Dharmayat KI,Stevens CAT,et al.Prevalence of Familial Hypercholesterolemia Among the General Population and Patients With Atherosclerotic Cardiovascular Disease:A Systematic Review and Meta-Analysis[J].Circulation,2020,141:1742- 1759.
• [24] Shi HW,Yang JG,Wang Y,et al.The Prevalence of Familial Hypercholesterolemia (FH) in Chinese Patients With Acute Myocardial Infarction (AMI):Data From Chinese Acute Myocardial Infarction (CAMI) Registry[J].Front Cardiovasc Med,2020,7:160.
• [25] Trinder M,Li X,Decastro ML,et al.Risk of Premature Atherosclerotic Disease in Patients With Monogenic Versus Polygenic Familial Hypercholesterolemia[J].J Am Coll Cardiol,2019,74:512- 522.
• [26] Perez De Isla L,Alonso R,Watts GF,et al.Attainment of LDL-Cholesterol Treatment Goals in Patients With Familial Hypercholesterolemia:5-Year SAFEHEART Registry Follow-Up[J].J Am Coll Cardiol,2016,67:1278- 1285.
• [27] Lloyd-Jones DM,Morris PB,Ballantyne CM,et al.2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk:A Report of the American College of Cardiology Task Force on Clinical Expert Conse[J].J Am Coll Cardiol,2016,68:92- 125.
• [28] Sturm AC,Knowles JW,Gidding SS,et al.Clinical Genetic Testing for Familial Hypercholesterolemia:JACC Scientific Expert Panel[J].J Am Coll Cardiol,2018,72:662- 680.
• [29] Sibbing D,Aradi D,Alexopoulos D,et al.Updated Expert Consensus Statement on Platelet Function and Genetic Testing for Guiding P2Y(12) Receptor Inhibitor Treatment in Percutaneous Coronary Intervention[J].JACC Cardiovasc Interv,2019,12:1521- 1537.
• [30] Simon T,Verstuyft C,Mary-Krause M,et al.Genetic determinants of response to clopidogrel and cardiovascular events[J].N Engl J Med,2009,360:363- 375.
• [31] Giusti B,Gori AM,Marcucci R,et al.Relation of cytochrome P450 2C19 loss-of-function polymorphism to occurrence of drug-eluting coronary stent thrombosis[J].J Am Coll Cardiol,2009,103:806- 811.
• [32] Sibbing D,Stegherr J,Latz W,et al.Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention[J].Eur Heart J,2009,30:916- 922.
• [33] Claassens DMF,Vos GJA,Bergmeijer TO,et al.A Genotype-Guided Strategy for Oral P2Y12 Inhibitors in Primary PCI[J].N Engl J Med,2019,381:1621- 1631.
• [34] Pereira NL,Farkouh ME,So D,et al.Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy on Ischemic Outcomes After Percutaneous Coronary Intervention:The TAILOR-PCI Randomized Clinical Trial[J].JAMA,2020,324:761- 771.
• [35] Ntaios G,Milionis H.Low-density lipoprotein cholesterol lowering for the prevention of cardiovascular outcomes in patients with ischemic stroke[J].Int J Stroke,2019,14:476- 482.
• [36] Hou Q,Li S,Li L,et al.Association Between SLCO1B1 Gene T521C Polymorphism and Statin-Related Myopathy Risk:A Meta-Analysis of Case-Control Studies[J].Medicine (Baltimore),2015,94:e1268.
• [37] Pandya A,Zhu J,Spahillari A.Cost- effectiveness of Statin Use Guidelines-Reply[J].JAMA Cardiol,2021,6:364.